In the private equity world, the term due diligence is most often associated with the verification of a target’s financial position and trading prospects. Yet, as it is so often said, private equity is a people business: so who, if anyone, does the industry turn to for assistance in this area and why is it that "human due diligence" processes remain so murky? Julian Longhurst reports.
Backers close a $18.6m round started in 2015 with an initial $10.6m capital injection
GP invests via its Nordic Capital Fund IX, which held a final close on €4.3bn in May 2018
Abalos Therapeutics is a biotechnology company focused on developing immuno-oncology therapeutics
Existing management team will lead the company's future growth and development